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Background: Edaravone is widely used to treat acute ischemic stroke (AIS) within
24 hours of onset. We aimed to evaluate current edaravone treatment practices and
the efficacy and safety of edaravone used with recombinant tissue plasminogen ac-
tivator (tPA) in AIS patients within 4.5 hours of onset. The results were compared
with those of the Safe Implementation of Treatments in Stroke-International Stroke
Thrombolysis Registry (SITS-ISTR) study. Methods: PROTECT4.5 was a prospec-
tive observational study conducted from April 2010 to March 2013 in Japan. The
primary end points were favorable outcomes (modified Rankin Scale score [mRS]
0-1) at 3 months after onset and incidence of symptomatic intracranial hemor-
rhage (sICH) within 36 hours of treatment. For comparison with SITS-ISTR, patients
were categorized based on the time from onset to treatment (within 3 hours of and
3-4.5 hours after onset) and baseline National Institutes of Health Stroke Scale score
(NIHSS). Results: Among the 11,384 registered patients, 11,126 and 8274 patients
were included in the safety and efficacy analysis populations, respectively. The
proportions of patients with mRS 0-1 receiving edaravone alone and edaravone + tPA
were 51.3% (95% confidence interval, 49.7%-52.8%) and 39.0% (37.6%-40.5%), re-
spectively. The incidence of sICH within 36 hours after tPA treatment (edaravone + tPA
group) was 1.6% (1.3%-2.0%). When compared with the SITS-ISTR results, those
treated with edaravone + tPA appeared to show better outcomes in patients with
NIHSS score ≥16. Conclusions: The efficacy and safety of edaravone combined
with tPA and administered within 4.5 hours of AIS onset were demonstrated with
From the *National Cerebral and Cardiovascular Center, Osaka, Japan; †Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Osaka, Japan;
‡Mitsubishi Tanabe Pharma Corporation, Yodogawa-ku, Osaka, Japan; and §Saitama Medical University, International Medical Center, Saitama,
Japan.
Received August 19, 2016; revision received September 27, 2016; accepted October 10, 2016.
Funding: The study was funded by Mitsubishi Tanabe Pharma Corporation (Osaka, Japan).
Conflicts of interest: TY has received consulting fees from Mitsubishi Tanabe Pharma Corporation, and lecture fees from Mitsubishi Tanabe
Pharma Corporation, Bayer Yakuhin, Pfizer Japan Inc., Otsuka Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Sanofi K.K., Nippon
Chemiphar, Eisai Co., Ltd., Bristol-Myers Squibb, Boehringer Ingelheim Japan, Inc., and Sumitomo Dainippon Pharma Co., Ltd. NT has also
received consulting fees from Mitsubishi Tanabe Pharma Corporation, and lecture fees from Mitsubishi Tanabe Pharma Corporation, AstraZeneca
K.K., Sanofi K.K., Boehringer Ingelheim Japan, Inc., Bayer Yakuhin, Ltd., and Takeda Pharmaceutical Company Ltd. HA and HM are em-
ployees of Mitsubishi Tanabe Pharma Corporation.
Author contributions: Drs Yamaguchi and Tanahashi supervised the study, and contributed to the interpretation of the results. Mr Awano
contributed to the interpretation of the results. Mr Matsuda contributed to the study design, data processing, and statistical analysis. All
authors contributed to manuscript preparation and have approved the final draft.
Address correspondence to Takenori Yamaguchi, MD, National Cerebral and Cardiovascular Center, 5-7-1 Suita, Osaka 565-8565, Japan.
E-mail: tyamaguc@ncvc.go.jp.
1052-3057/$ - see front matter
© 2016 The Authors. Published by Elsevier Inc. on behalf of National Stroke Association. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2016.10.011
ARTICLE IN PRESS
Journal of Stroke and Cerebrovascular Diseases, Vol. ■■, No. ■■ (■■), 2016: pp ■■–■■ 1
numerically lower incidence of sICH and better outcomes. Key Words: Acute ischemic
stroke—edaravone—Japan—prospective observational study—recombinant tissue
plasminogen activator—symptomatic intracranial hemorrhage.
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Introduction
Edaravone (EDV), a free radical scavenger developed
in Japan, strongly suppresses the peroxidation reaction
of lipids in the arachidonate cascade,1 which is en-
hanced by cerebral ischemia, and inhibits vascular
endothelial cell damage, cerebral edema, and delayed neu-
ronal death.2 Based on a Japanese study of acute ischemic
stroke (AIS) patients,3 edaravone was approved in Japan
by the Ministry of Health, Labour and Welfare for the
treatment of ischemic stroke within 24 hours of onset,
and is widely used for AIS within 24 hours of onset fol-
lowing the guidelines for stroke management.4-6
The efficacy and safety of intravenous recombinant tissue
plasminogen activator (tPA) were shown up to 4.5 hours
after onset in the European Cooperative Acute Stroke Study
(ECASS-III)7 and in a large-scale cohort study (Safe Im-
plementation of Treatments in Stroke-International Stroke
Thrombolysis Registry [SITS-ISTR]).8 Subsequently, the Eu-
ropean Stroke Organization recommended that the
therapeutic time window (TTW) of tPA should be ex-
tended to 4.5 hours after onset.9 Thereafter, the American
Heart Association and the American Stroke Association
made similar revisions.10
In 2005, alteplase, a tPA, was approved in Japan at a
dose of .6 mg/kg, which is lower than that used in other
countries (.9 mg/kg), based on the results of the Japan
Alteplase Clinical Trial.11 In 2013, the TTW was ex-
tended to “within 4.5 hours of symptom onset,”12 in
response to the ECASS-III7 and SITS-ISTR results.8
PROTECT4.5 (Postmarketing Registry On Treatment with
Edaravone in acute Cerebral infarction by the Time window
of 4.5 h) aimed to evaluate the current practices in
edaravone treatment in patients with AIS and the effi-
cacy and safety of edaravone used with tPA
(edaravone + tPA) at .6 mg/kg, when administered within
4.5 hours of onset. In an additional post-hoc analysis that
was not predefined, the efficacy and safety of
edaravone + tPA are compared with the results of SITS-
ISTR (tPA alone).13
Methods
PROTECT4.5 was a prospective cohort study per-
formed in clinical practice for the postmarketing
surveillance of edaravone conducted by Mitsubishi Tanabe
Pharma Corporation (Osaka, Japan). PROTECT4.5 was con-
ducted in accordance with the Good Postmarketing Study
Practice guidelines specified by the Ministry of Health,
Labour and Welfare at 1121 institutions specializing in
the treatment of AIS in Japan (Supplementary File S1).
The targeted sample size was 10,000 patients, and the study
was conducted from April 2010 to March 2013. The trial
is registered under the number UMIN000009227.
The inclusion criteria were as follows: AIS patients re-
ceiving EDV within 4.5 hours of onset, a consciousness
level of 0-30 by the Japan Coma Scale,14 and weakness
in the upper or lower limbs (hemiparesis or hemiple-
gia). The exclusion criteria were baseline serum creatinine
level >1.5 mg/dL, history of hypersensitivity to compo-
nents of EDV, ineligibility to participate in the study as
judged by the attending physician because of the pres-
ence of severe liver disease (e.g., hepatic cirrhosis) or heart
disease (e.g., congestive heart failure) requiring hospi-
talization, infection-related complications requiring
administration of antibiotics, or other reasons; modified
Rankin Scale score [mRS] ≥2 before onset; severe neu-
rologic deficit (National Institutes of Health Stroke Scale
[NIHSS]: ≥23) before EDV treatment; history of cerebral
infarction within 3 months; complicated with intracra-
nial hemorrhage; and showing marked improvement in
neurologic symptoms and signs, with a high probabili-
ty of transient ischemic attack. Patients were registered
within 6 days after onset.
Patients were treated with edaravone alone or
edaravone + tPA depending on their clinical condition and
the time of arrival at the hospital. A 30-mg dose of
edaravone was diluted with saline and administered twice
daily in the morning and late afternoon by intravenous
infusion for 30 minutes, for several days. The tPA was
administered according to the dosage regimen ap-
proved in Japan (10% of a dose [.6 mg/kg] of tPA was
given by rapid intravenous injection; the rest was given
by intravenous infusion for 1 hour).
The primary end point measures were favorable out-
comes (mRS 0-1) at 3 months after onset and incidence
of symptomatic intracranial hemorrhage (sICH) within
36 hours of treatment. When comparing the incidence of
sICH between those in the present study who received
treatment with edaravone + tPA (the PROTECT4.5-tPA pop-
ulation) and SITS-ISTR, the incidence of sICH after tPA
treatment was defined as follows: First, sICH within 36
hours after tPA treatment was defined according to the
SITS-Monitoring Study (SITS-MOST) definition.15 Second,
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sICH within 7 days after tPA treatment was defined ac-
cording to the ECASS-II definition.16
Statistical Analysis
The proportion and the 95% confidence interval of pa-
tients with mRS 0-1 and incidence of sICH were calculated.
PROTECT4.5 did not include patients treated with tPA
alone. To compare our results with those of SITS-ISTR
in which patients were treated with tPA alone,13 a dataset
for the PROTECT4.5-tPA population (including only pa-
tients with a baseline NIHSS score ≤25 and aged 18-80
years) was prepared to adjust for baseline characteris-
tics and was divided into two groups based on the time
from onset to tPA treatment: one group included pa-
tients treated within 3 hours of onset and the other
included those treated during the period of 3-4.5 hours
after onset. The Pearson chi-square test was used to
compare the proportion of patients with mRS 0-1 and mRS
6 stratified by baseline NIHSS and the incidence of sICH
within 36 hours in the PROTECT4.5-tPA population, and
the proportions and incidences stated in a figure from
the article by Ahmed et al from SITS-ISTR.13 This anal-
ysis was performed using values obtained from the article,
not from the authors of the SITS-ISTR study. Statistical
significance was considered as a two-tailed probability
of less than .05 without any correction based on a mul-
tiple comparison approach. All analyses were performed
using SAS version 9.3 (SAS Institute, Cary, NC).
Results
Disposition of Patients
A total of 11,384 patients were registered. Among them,
11,126 patients (847 centers) from whom case report forms
were available were evaluated as the safety analysis pop-
ulation (SAFP). Of the 11,126 patients, 8274 patients in
whom the mRS was evaluated at 3 months after onset
were used for the efficacy analysis population (EFFP). The
number of patients whose baseline characteristics were
adjusted for comparison with SITS-ISTR was 8052 for the
safety evaluation (modified SAFP) and 6130 for the ef-
ficacy evaluation (modified EFFP) (Fig 1). Some patients
with a baseline NIHSS score ≥23 were registered, despite
this being an exclusion criterion.
Patient Baseline Characteristics
The median age was 74 years in patients receiving
edaravone alone or edaravone + tPA. The median NIHSS
score was 6 and 13 in patients receiving edaravone alone
and edaravone + tPA, respectively (Table 1). In most patients
receiving edaravone alone and edaravone + tPA, the NIHSS
score was within 0-5 and 6-20, respectively (Fig 2, A).
Efficacy and Safety
The proportion of patients with mRS 0-1 at 3 months
after onset was 51.3% in those receiving edaravone alone
and 39.0% in those receiving edaravone + tPA. The
Figure 1. Disposition of patients. Abbreviations: CRF, case report form; mRS, modified Rankin Scale score; NIHSS, National Institutes of Health Stroke
Scale score; Pts, patients; SITS-ISTR, Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Registry; tPA, recombinant tissue
plasminogen activator.
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incidence of sICH within 36 hours after edaravone treat-
ment was .5% in patients receiving edaravone alone and
1.6% in those receiving edaravone + tPA (Table 2).
Comparison with SITS-ISTR: A Post-Hoc Analysis
Baseline Characteristics (PROTECT4.5-tPA
Population)
The baseline characteristics of patients in the
PROTECT4.5-tPA population divided into two groups by
the time from onset to tPA treatment (within 3 hours and
3-4.5 hours) are shown in Table 3. In both study groups,
approximately 30% of the patients had NIHSS scores before
treatment of 6-10 (Fig 2, B,C).
Distributions of the mRS (PROTECT4.5-tPA and
SITS-ISTR Populations)
Figure 3A,B shows the mRS at 3 months after onset
in the PROTECT4.5-tPA and SITS-ISTR populations, divided
into two groups based on the time from onset to tPA treat-
ment (within 3 hours and 3-4.5 hours) and stratified by
baseline NIHSS scores (≤5, 6-10, 11-15, 16-20, and 21-25).
Among patients with NIHSS scores of 16-20 or 21-25 in
the 3-hour group, the proportion of patients with mRS
0-1 was significantly higher in those receiving
edaravone + tPA (PROTECT4.5-tPA) than in those receiv-
ing tPA alone (SITS-ISTR) (both P < .0001). Among patients
with NIHSS scores of 11-15, 16-20, or 21-25 in the 3-hour
group, the death rate was significantly lower in
PROTECT4.5-tPA than in SITS-ISTR (all P < .0001).
Incidence of sICH (PROTECT4.5-tPA and SITS-ISTR
Populations)
The incidences of sICH within 36 hours (SITS-MOST def-
inition) in the PROTECT4.5-tPA and SITS-ISTR populations
were 1.5% and 1.7%, respectively, in the 3-hour group, and
1.5% and 2.2%, respectively, in the 3–4.5-hour group. The
incidences of sICH within 7 days (ECASS-II definition) in
the PROTECT4.5-tPA and SITS-ISTR populations were 1.8%
and 4.8%, respectively, in the 3-hour group, and 3.0% and
5.3%, respectively, in the 3–4.5-hour group. The incidence
of sICH based on the ECASS-II definition in the 3-hour
group was significantly lower in PROTECT4.5-tPA than in
SITS-ISTR (P < .0001) (Fig 3, C,D).
Discussion
Because there was no control group for the edaravone
alone group, we cannot make any comments on the
Table 1. Patient baseline characteristics (safety analysis population)
Characteristics
Edaravone alone Edaravone + tPA
N = 5155 N = 5971
Age, years 74 (65-81) 74 (66-81)
Sex, women 1874 (36.4) 2275 (38.1)
Prestroke independence, mRS 0-1 5039 (97.7) 5891 (98.7)
Concomitant disease
Hypertension 3131 (60.7) 3522 (59.0)
Diabetes mellitus 1005 (19.5) 1042 (17.5)
Atrial fibrillation 1334 (25.9) 2038 (34.1)
Ischemic heart disease 400 (7.8) 434 (7.3)
Heart failure 250 (4.8) 345 (5.8)
Valvular disease 134 (2.6) 167 (2.8)
Previous stroke <3 months before 16 (.3) 4 (.1)
Baseline NIHSS 6 (3-12) 13 (8-18)
Subtype of ischemic stroke
Cardioembolic 1878 (36.4) 3414 (57.2)
Atherothrombotic 1589 (30.8) 1577 (26.4)
Lacunar 1310 (25.4) 570 (9.5)
Others 376 (7.3) 408 (6.8)
Dosage periods of edaravone (days) 9 (7-14) 9 (7-14)
Time from onset to edaravone treatment (min) 180 (120-210) 120 (90-165)
Time from onset to tPA treatment (min) – 137 (114-165)
Treatment with antiplatelets before onset 1234 (23.9) 1279 (21.4)
Treatment with anticoagulants before onset 598 (11.6) 645 (10.8)
Abbreviations: mRS, modified Rankin Scale score; NIHSS, National Institutes of Health Stroke Scale score; tPA, recombinant tissue plas-
minogen activator.
Data are presented as median (interquartile range) or N (%).
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efficacy and safety of edaravone as a neuroprotective agent.
Data showing better outcomes in the edaravone alone
group were due to the low baseline NIHSS scores in this
group of patients. Most of the patients who received treat-
ment during the period of 3-4.5 hours after onset were
treated with edaravone alone because the registration period
after the extension of the TTW was very short.
Edaravone + tPA showed more favorable outcomes (mRS
0-1) than another Japanese clinical study of tPA with or
without edaravone, the Japan post-marketing alteplase
Figure 2. Distribution of patients based on the
NIHSS: (A) efficacy analysis population, (B) modi-
fied efficacy analysis population within 3 hours of
onset, and (C) modified efficacy analysis popula-
tion 3-4.5 hours after onset. Abbreviations: NIHSS,
National Institutes of Health Stroke Scale score; SITS-
ISTR, Safe Implementation of Treatments in Stroke-
International Stroke Thrombolysis Registry; tPA,
recombinant tissue plasminogen activator.
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registration study (J-MARS),16 and a numerically lower
incidence of sICH; therefore, the efficacy and safety of
edaravone + tPA were demonstrated. In a post-hoc anal-
ysis, for patients with NIHSS scores ≥16 in the 3-hour
group, the proportion of patients having favorable out-
comes was significantly higher, and for patients with NIHSS
scores ≥11 in the 3-hour group, the death rate was sig-
nificantly lower among patients receiving edaravone + tPA
(PROTECT4.5-tPA) than in those receiving tPA-alone (SITS-
ISTR) (P < .0001, respectively). Although no complete
Table 2. Overall efficacy and safety of edaravone
Edaravone alone Edaravone + tPA
Efficacy analysis population N = 3927 N = 4347
mRS at 3 months after onset
0 1005 (25.6) 901 (20.7)
1 1008 (25.7) 795 (18.3)
0-1 2013 (51.3; 49.7-52.8) 1696 (39.0; 37.6-40.5)
2 559 (14.2) 594 (13.7)
3 318 (8.1) 452 (10.4)
4 492 (12.5) 794 (18.3)
5 288 (7.3) 450 (10.4)
6 257 (6.5) 361 (8.3)
Safety analysis population N = 5155 N = 5971
Adverse events 598 (11.6; 10.7-12.5) 1091 (18.3; 17.3-19.3)
Intracranial hemorrhage 175 (3.4; 2.9-3.9) 530 (8.9; 8.2-9.6)
All sICH 54 (1.0; .8-1.4) 146 (2.4; 2.1-2.9)
sICH within 36 hours after edaravone treatment 26 (.5; .3-.7) 96 (1.6; 1.3-2.0)
sICH within 36 hours after tPA treatment – 98 (1.6; 1.3-2.0)
Severe adverse events 368 (7.1; 6.5-7.9) 662 (11.1; 10.3-11.9)
Fatal adverse events 154 (3.0; 2.5-3.5) 218 (3.7; 3.2-4.2)
Edaravone-related adverse reactions 206 (4.0; 3.5-4.6) 349 (5.8; 5.3-6.5)
Abbreviations: mRS, modified Rankin Scale score; sICH symptomatic intracranial hemorrhage; tPA, recombinant tissue plasminogen activator.
Data are N (%; 95% confidence interval).
Table 3. Baseline characteristics of the PROTECT4.5-tPA and SITS-ISTR populations
Within 3 hours of onset 3-4.5 hours after onset
PROTECT4.5-tPA SITS-ISTR PROTECT4.5-tPA SITS-ISTR
N = 4065 N = 25,279 N = 334 N = 4056
Edaravone + tPA tPA alone Edaravone + tPA tPA alone
Age, years 70 63-75 68 58-74 70 65-75 67 57-74
Sex, women 1260/4065 31.0% 8546/21,566 39.6% 115/334 34.4% 1020/2376 42.9%
mRS 0-1 before stroke 4029/4065 99.1% 19,377/20,931 92.6% 330/334 98.8% 2089/2277 91.7%
Hypertension 2294/4065 56.4% 12,806/21,149 60.6% 209/334 62.6% 1416/2324 60.9%
Diabetes mellitus 757/4065 18.6% 3369/21,273 15.8% 71/334 21.3% 387/2344 16.5%
Atrial fibrillation 1243/4065 30.6% 4763/21,069 22.6% 93/334 27.8% 494/2334 21.2%
Heart failure 175/4065 4.3% 1611/21,181 7.6% 14/334 4.2% 184/2334 7.9%
Previous stroke ≤3 months
before
4/4065 .1% 2213/21,314 10.4% 0/334 0% 257/2357 10.9%
Baseline NIHSS 12 8-17 12 7-17 10 6-16 10 6-15
Time from onset to tPA
treatment (min)
133 110-157 140 114-165 210 190-237 205 190-229
Abbreviations: mRS, modified Rankin Scale score; NIHSS, National Institutes of Health Stroke Scale score; SITS-ISTR, Safe Implemen-
tation of Treatments in Stroke-International Stroke Thrombolysis Registry; tPA, recombinant tissue plasminogen activator.
Data are presented as median, interquartile range or N, %. For comparison with SITS-ISTR, a dataset of PROTECT4.5 (the PROTECT4.5-
tPA population including only patients with a baseline NIHSS score ≤25 and aged 18-80 years) was prepared to adjust for baseline characteristics.
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Figure 3. Comparisons between PROTECT4.5-tPA (edaravone + tPA) and SITS-ISTR (tPA alone). Comparison of mRS at 3 months between PROTECT4.5-
tPA and SITS-ISTR populations stratified by baseline NIHSS within (A) 3 hours of onset and (B) 3-4.5 hours after onset. Among patients with an NIHSS
score ≥16, the proportion of patients with mRS 0-1 was higher in those receiving edaravone + tPA than in those receiving tPA alone. Incidence of sICH (according
to SITS-MOST [C] and ECASS II [D] definitions) among PROTECT4.5-tPA and SITS-ISTR populations. The SITS-MOST definition was local or remote
parenchymal hematoma type 2 (exceeding 30% of the infarct volume with a significant space-occupying effect) on the imaging scan obtained 22-36 hours after
rt-PA treatment, plus neurologic deterioration, as indicated by NIHSS score ≥4 points higher than the baseline value or the lowest value between baseline and
24 hours, or hemorrhage leading to death. However, in PROTECT4.5, the size of the hemorrhage was not considered. The ECASS II definition was any
hemorrhage with neurologic deterioration, as indicated by NIHSS score ≥4 points higher than the value at baseline or the lowest value in the first 7 days, or
any hemorrhage leading to death. Abbreviations: ECASS, European Cooperative Acute Stroke Study; mRS, modified Rankin scale score; NIHSS, National
Institutes of Health Stroke Scale score; sICH, symptomatic intracranial hemorrhage; SITS-ISTR, Safe Implementation of Treatments in Stroke-International
Stroke Thrombolysis Registry; SITS-MOST, Safe Implementation of Treatments in Stroke-Monitoring Study; tPA, recombinant tissue plasminogen activator.
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unbiased adjusted estimates could be calculated to compare
PROTECT4.5-tPA and SITS-ISTR populations, the find-
ings suggest that edaravone + tPA may increase the
proportion of patients having favorable outcomes and de-
crease the death rate compared with tPA alone, particularly
in patients treated within 3 hours of onset and with an
NIHSS score ≥16. There were no such differences in the
proportion of patients having favorable outcomes (mRS
0-1) and death (mRS 6) between both groups (PROTECT4.5-
tPA and SITS-ISTR) among those who had an NIHSS score
≤10. Similar results were obtained among patients treated
within 3 hours of and 3-4.5 hours after onset, but the
number of subjects in PROTECT4.5 was not large enough
for comparison.
The incidence of sICH within 36 hours after tPA treat-
ment (SITS-MOST definition) was lower in the
PROTECT4.5-tPA populations than in SITS-ISTR among
patients treated within 3 hours of onset. The same results
were obtained in patients treated during 3-4.5 hours after
onset. The SITS-MOST definition of sICH considers the
hemorrhage size (parenchymal hematoma type 2) in brain
imaging. However, in PROTECT4.5, the size of the hem-
orrhage was not accounted for. Thus, the quantification
of sICH in the PROTECT4.5 population may have in-
cluded even small hemorrhages if neurologic symptoms
and signs deteriorated. When comparing the incidence
of sICH within 7 days after tPA treatment (ECASS-II
definition) between the two studies, the incidence was
Figure 3. (continued)
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significantly lower in PROTECT4.5-tPA than in SITS-
ISTR in the 3-hour group (P < .0001).
The fact that the incidence of sICH in the PROTECT4.5-
tPA populations was lower than that reported in SITS-
ISTR may possibly be due to the lower dose of tPA (.6 mg/
kg) used in Japan compared with that used in other
countries (.9 mg/kg). The incidences of sICH within 36
hours after tPA treatment in Japanese clinical studies of
tPA (.6 mg/kg) such as the Japan Alteplase Clinical Trial11
(tPA alone), J-MARS17 (tPA with or without edaravone),
and PROTECT4.5 (edaravone + tPA) were 5.8%, 3.5%, and
1.6%, respectively, which suggests that edaravone + tPA
may decrease the incidence of sICH.
Edaravone exerts a neuroprotective effect by suppress-
ing the accumulation of lipid peroxidation products and
oxidative DNA damage and eliminating the sequential
inflammatory responses after ischemia and reperfusion.18
This mechanism is thought to contribute to the clinical
efficacy of edaravone and to the decrease in incidence
of sICH when edaravone is added to tPA.
In the neurovascular unit, edaravone suppresses the
dissociation of astrocyte endfeet from the basement mem-
brane induced by tPA,19 and prevents the expression and
activation of matrix metalloproteinase-9 and oxidative stress
damage caused by tPA treatment, which destroy the blood–
brain barrier.20,21 This mechanism is supposed to suppress
the incidence of sICH. Edaravone added to tPA has been
reported to improve functional outcome, improve the
recanalization rate of occluded arteries, and decrease
the incidence of intracranial hemorrhage.22,23 Therefore,
in the present study, the low incidence of sICH in the
edaravone + tPA group is thought to be due to the sup-
pression of sICH by protection of the neurovascular unit
and blood–brain barrier.
The sICH after tPA treatment could deteriorate the final
outcome of patients with cerebral infarction.24 In the present
study, the proportion of patients with sICH and mRS 5-6
at 3 months after onset with edaravone + tPA was 66%
(82 out of 125). The incidences of sICH according to both
the SITS-MOST and ECASS-II definition were lower in
the PROTECT4.5-tPA population than those in SITS-
ISTR. These results suggest that edaravone + tPA decreased
the proportion of patients having unfavorable outcomes
(mRS 5-6) by decreasing the incidence of sICH.
The present study has many limitations. First, this was
an observational and nonrandomized study. Because pa-
tients were enrolled within 6 days after onset, there may
have been selection bias as many cases of sICH occur
within this period. Second, there may have been bias in
the comparison between SITS-ISTR and PROTECT4.5-
tPA population data because a complete adjustment could
not be applied. Third, because the population size was
notably smaller in PROTECT4.5-tPA than SITS-ISTR, the
comparison of mRS stratified by baseline NIHSS scores
should be interpreted with caution. Fourth, because the
hemorrhage size was not considered in the PROTECT4.5-
tPA population, based on the SITS-MOST definition of
sICH, the incidence may have been lower than that in
SITS-ISTR.
In conclusion, the efficacy and safety of edaravone com-
bined with tPA and administered within 4.5 hours of AIS
onset were demonstrated with numerically lower inci-
dence of sICH after tPA administration and better
outcomes.
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